CDR2

Across TCGA pan-cancer cohorts, CDR2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CDR2 data layer compared with 27 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher CDR2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CDR2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and PDAC show a favorable association.

HNSC, LSCC, and CCRCC are the cancer types where CDR2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	III,IV	0.690	0.386	.006	49	view →
LSCC	OS	Median	II,III,IV	0.897	1.000	.011	13	view →
CCRCC	DFS	Median	All	0.725	0.896	.032	7	view →
PDAC	OS	Tertile	III,IV	0.503	0.220	.010	5	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CDR2–HNSC (DFS)

Open the HNSC breakdown →